K

M

MPM Capital

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series B

U
Umoja Biopharma

Biotechnology • In vivo cell therapies

University of Minnesota Endowment logo
SoftBank logo
RTW Investments logo
Qiming Venture Partners USA logo

Umoja Biopharma is a biotechnology company focused on developing in vivo CAR T cell therapies for oncology and autoimmune diseases using its VivoVec™ gene delivery technology.

Series C
$100M
01/20/2025
Article
C
Concept Matrix Solutions

Biotechnology • IP Portfolio Growth

Impact Biotech logo

Concept Matrix Solutions, Inc. (CMS) is a biotechnology company focused on expanding its IP portfolio, enhancing research and development capabilities, and acquiring lab equipment with the recent investment from Impact Biotech, LLC.

Equity
$1.2M
11/07/2023
Article
A
AstronauTx

Biotech • Alzheimer's Disease Treatment

Novartis logo
MPM Capital logo
EQT Life Sciences logo
Dementia Discovery Fund logo

AstronauTx is a London-based biotech company that develops small-molecule drugs for the treatment of Alzheimer's disease, and has raised £48 million ($61 million) in Series A financing to advance its drug portfolio, including conducting a clinical study for its lead program.

Series A
$58.6M
10/09/2023
Article
D
Deka Biosciences

Biotech • Immunotherapy

MPM BioImpact logo
Viva BioInnovator logo
Plains Ventures logo
Lumira Ventures logo

Deka Biosciences is a biotech company that aims to improve immunotherapy treatments by combining biology with precision medicine, specifically through their investigational new drug, DK210 (EGFR), which has dissociated IL-2 potency from toxicity.

Series B
$20M
09/28/2023
Article
R
ReCode Therapeutics

Genetic Medicines • MRNA Therapeutics

Bioluminescence Ventures logo
Solasta Ventures logo
Sanofi Ventures logo
Pfizer Ventures logo

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

Series B
$50M
09/19/2023
Article
A
Arialys Therapeutics

Biotechnology • Neuropsychiatric Disorders

MPM BioImpact logo
Johnson & Johnson Innovation logo
Catalys Pacific logo
Avalon BioVentures logo

Arialys Therapeutics is a biotechnology company that develops precision medicines to target pathogenic autoantibodies in the central nervous system, with a focus on treating neuropsychiatric diseases caused by autoimmunity.

Seed
$58M
09/13/2023
Article